Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targets in Thyroid Cancer.

Wei ZhangShuhuang LinZhuo WangWenyong ZhangMingzhao Xing

Published in: The Journal of clinical endocrinology and metabolism (2024)

Coexisting RET/PTC and TERT promoter mutation identify PTC as a unique clinical entity with high mortality, providing new implications for genetic-based prognostication and potential therapeutic targeting of RET and MEK guided by RET/PTC and TERT status.

Keyphrases

poor prognosis
long non coding rna
dna methylation
gene expression
transcription factor
pi k akt
type diabetes
cancer therapy
risk factors
signaling pathway
copy number
cell proliferation